NL-OMON55177Not yet recruitingNot Applicable
Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial - ADDORA-low
Reade0 sites89 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 89
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 16 to 64 (—)
Inclusion Criteria
- •Rheumatoid arthritis patient, according to ACR 1987/2010 criteria;
- •Treated for at least 28 weeks with adalimumab
- •Adalimumab trough concentration >5mg/L
- •Who has agreed to participate (written informed consent);
- •Age 16 years or older.
Exclusion Criteria
- •Scheduled surgery during the follow-up of the study or other pre-planned
- •reasons for treatment discontinuation
- •Life expectancy shorter than follow-up period of the study;
- •No other disease that might flare if adalimumab is tapered like psoriasis,
- •inflammatory bowel disease
Investigators
Similar Trials
Active, not recruiting
Phase 1
Adalimumab dose reduction aiming low drug levels with control of disease activity (ADDORA-LOW)Rheumatoid arthritisEUCTR2019-001793-28-NLReade89
Recruiting
Not Applicable
Adalimumab dose reduction aiming low serum concentration with control of disease activityRheumatoid arthritisNL-OMON24020Reade Rheumatology Research Institute89
Terminated
Phase 4
Dose Tapering Study of Adalimumab in PsoriasisPsoriasis VulgarisNCT04028713University Hospital, Ghent19
Completed
Phase 4
A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are OvertreatedPsoriasisNCT05683054University Hospital, Ghent19
Completed
Phase 4
Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease ActivityRheumatoid ArthritisNCT04222920Reade Rheumatology Research Institute78